P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression

      Psychedelics are rapidly gaining ground as an intervention of interest for severe mood and anxiety disorders. The focus for most of this research is for patients who have failed four or fewer adequate interventions. Few trials of any intervention have looked at patients with depression who have failed more than four treatments in the current episode. This is a pilot study looking at the open label administration of 25 mg of synthetic psilocybin in ten patients with documented failures of at least five treatments in the current depressive episode.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect